Austar Lifesciences Limited (6118) Expects Significant Profit Growth for 2025

Bulletin Express

Feb 06

Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with approximately RMB16 million in 2024. The expected increase is mainly attributed to reduced operating expenses through strategic efficiency measures, higher exchange gains, and lower finance costs.

According to the company’s management, these indicators reflect optimized administrative and R&D spending, supported by organizational streamlining to enhance financial flexibility and focus on strategic growth areas. The figures remain subject to finalization and review by auditors, with official annual results slated for release in late March 2026.

Investors are advised to exercise caution when trading the company’s shares, as the figures are based on preliminary data and may be adjusted following the conclusion of the audit process.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143338277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143338277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143338277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143338277","market":"hk","top_or_hot":-1,"title":"Austar Lifesciences Limited (6118) Expects Significant Profit Growth for 2025","media":"Bulletin Express","content":"<p>Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with approximately RMB16 million in 2024. The expected increase is mainly attributed to reduced operating expenses through strategic efficiency measures, higher exchange gains, and lower finance costs.</p>\n<p>According to the company’s management, these indicators reflect optimized administrative and R&D spending, supported by organizational streamlining to enhance financial flexibility and focus on strategic growth areas. The figures remain subject to finalization and review by auditors, with official annual results slated for release in late March 2026.</p>\n<p>Investors are advised to exercise caution when trading the company’s shares, as the figures are based on preliminary data and may be adjusted following the conclusion of the audit process.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Austar Lifesciences Limited (6118) Expects Significant Profit Growth for 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAustar Lifesciences Limited (6118) Expects Significant Profit Growth for 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-06 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with approximately RMB16 million in 2024. The expected increase is mainly attributed to reduced operating expenses through strategic efficiency measures, higher exchange gains, and lower finance costs.</p>\n<p>According to the company’s management, these indicators reflect optimized administrative and R&D spending, supported by organizational streamlining to enhance financial flexibility and focus on strategic growth areas. The figures remain subject to finalization and review by auditors, with official annual results slated for release in late March 2026.</p>\n<p>Investors are advised to exercise caution when trading the company’s shares, as the figures are based on preliminary data and may be adjusted following the conclusion of the audit process.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06118","symbol_name":"奥星生命科技","start_time":0,"source_url":"","article_id":"1143338277","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143338277","pubTimestamp":1770367499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06118":"奥星生命科技"},"translate_title":"奥星生命科技有限公司(6118)预计2025年盈利大幅增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06118":1},"content_text":"Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with approximately RMB16 million in 2024. The expected increase is mainly attributed to reduced operating expenses through strategic efficiency measures, higher exchange gains, and lower finance costs.\nAccording to the company’s management, these indicators reflect optimized administrative and R&D spending, supported by organizational streamlining to enhance financial flexibility and focus on strategic growth areas. The figures remain subject to finalization and review by auditors, with official annual results slated for release in late March 2026.\nInvestors are advised to exercise caution when trading the company’s shares, as the figures are based on preliminary data and may be adjusted following the conclusion of the audit process.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}